GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average rating of “Hold” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $4.7292.

A number of equities analysts have recently weighed in on the stock. Bank of America reissued a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. JPMorgan Chase & Co. reduced their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Mizuho lowered their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Citigroup cut their price objective on GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Friday, January 9th. Finally, UBS Group lowered their target price on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th.

Institutional Investors Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. LSV Asset Management boosted its position in GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock valued at $9,960,000 after purchasing an additional 1,973,017 shares during the last quarter. XTX Topco Ltd raised its stake in shares of GoodRx by 281.2% during the 2nd quarter. XTX Topco Ltd now owns 272,273 shares of the company’s stock worth $1,356,000 after purchasing an additional 200,852 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of GoodRx in the 3rd quarter valued at approximately $3,036,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of GoodRx by 16.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after buying an additional 236,896 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new position in GoodRx during the third quarter worth $3,687,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $2.36 on Friday. The firm’s 50 day simple moving average is $2.57 and its 200 day simple moving average is $3.33. GoodRx has a fifty-two week low of $2.10 and a fifty-two week high of $5.81. The company has a market capitalization of $801.05 million, a price-to-earnings ratio of 26.22, a P/E/G ratio of 0.90 and a beta of 1.50. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.